EUCTR2015-001903-30-DK进行中（未招募）1 期
Effect of tolvaptan on RBF and GFR in ADPKD - Tolvaptan and RPF in ADPKD
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age > 18 years
- •Diagnosis with ADPKD
- •Informed consent
- •Contraception for fertile women
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •Renal transplantation
- •Operation in the kidnety
- •Diabetes mellitus
- •Neoplastic conditions
- •Pregnancy, nursing
- •Unwillingness to participate
- •eGFR > 30
- •Intolerans towrds tolvaptan
- •Alkohol or medical abuse,
- •BP >>170/110 blodtryk despite regulation
研究者
相似试验
已完成
3 期
Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKDPolycystic Kidney, Autosomal DominantNCT03803124Regional Hospital Holstebro20
已完成
不适用
Change in eGFR after adminstration of tolvaptan and furosemide in liver cirrhosis patients with ascites:a randomized studyliver cirrhosisJPRN-UMIN000023881shonan kamakura general hospital36
已完成
不适用
10-year tolvaptan in ADPKD - A patient-based center evaluatioQ61.2Polycystic kidney, autosomal dominantDRKS00019856Otsuka Pharma GmbH13
已完成
3 期
Tolvaptan Extension Study in Participants With ADPKDAutosomal Dominant Polycystic Kidney Disease (ADPKD)NCT01214421Otsuka Pharmaceutical Development & Commercialization, Inc.1,083
已完成
不适用
Features of responders to Tolvaptan in CKD patientsChronic kidney diseaseJPRN-UMIN000013366Department of Nephrology, Tokyo Medical and Dental University75